Philips introduces VitalMinds, new non-pharmacological approach to help reduce delirium in the ICU
April 25 2019 - 8:00AM
Philips introduces VitalMinds, new non-pharmacological approach to
help reduce delirium in the ICU
April 25, 2019
- Key technology of the multi-component solution is the VitalSky
personalized light therapy system, now with CE Mark as a medical
device
- VitalSky improves sleep quality in intensive care patients to
help reduce delirium
Amsterdam, The Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology today
introduced VitalMinds, an integrated multi-component solution
focused on supporting hospitals with a non-pharmacological approach
to reducing delirium. A unique, key component of the approach is
VitalSky, a personalized light therapy system, designed for
clinical use in the intensive care unit (ICU). The innovative
system recently received CE Mark and is now commercially available
in Germany, Austria, Switzerland, Finland and Sweden, with market
launches planned in other European countries over the next two
years.
Delirium challenge in Intensive Care
MedicineDelirium, a serious disturbance in mental
abilities that results in confused thinking and reduced awareness
of the environment, occurs in 30% to 80% of all ICU patients,
making it the most common form of cognitive dysfunction in
intensive care medicine [1]. The occurrence of this cerebral
impairment during intensive care treatment has far-reaching
consequences, doubling the mortality risk of patients in ICUs and
even tripling mortality in the first six months following discharge
from the hospital [1,2]. In view of these statistics, guidelines
recommend systematic delirium screening for all patients in ICUs
and the implementation of non-pharmacological interventions to
prevent delirium, such as mobilizing patients during the day and
introducing measures to promote sleep at night [3].
“With VitalMinds, we have developed a new concept that combines
light and sound management, circadian-effective light therapy,
staff training and consulting services, to help hospitals reduce
delirium and improve patient recovery in the ICU,” said Felix
Baader, Business Leader, Monitoring Analytics at Philips. “This
integrated approach is based on international ICU guidelines and
supports hospitals in achieving the quadruple aim to improve
patient and staff experience, deliver better health outcomes, and
drive lower costs in intensive care medicine.”
VitalSky for Personalized Light Therapy The
VitalSky light therapy system provides a circadian-effective
program to support the sleep-wake rhythm of patients. This program
simulates the natural progression of daylight using a spectrum of
glare-free white light provided by a large luminous LED ceiling.
The light conditions can be personalized to the needs of the
individual patient. The system also provides premium-quality
workplace lighting to support favorable treatment conditions.
Advanced features include the additional option of playing calming
nature scenes in full-color, soft-focus video, and the future
enablement of cognitive training is also planned. The various
programs and settings can be selected and adjusted quickly and
easily via a portable user interface.
“In the framework of a multi-component approach at Marien
Hospital in Wesel, Germany, we aim to prevent delirium in the ICU.
For this purpose, the light therapy technology of the VitalSky
system is an essential environmental element which will help us to
support the circadian rhythm of patients,” said Dr. Marc Achilles,
Chief Physician of anesthesiology and intensive care medicine,
Marien Hospital. “We are proud to be the first hospital worldwide
where this system is installed.”
Improved Patient Environment Supports the Reduction of
DeliriumRecent results from the VITALITY study of the
Charité University Hospital in Berlin demonstrate the important
role of an improved patient environment, including
circadian-effective light therapy for the recovery process and the
prevention of delirium in the ICU. The preliminary results of the
VITALITY study show a statistically significant reduction of 39% in
the incidence of delirium for patients treated in modified ICU
rooms compared to patients treated in standard rooms [4].
More information on the VITALITY study results is available
here. For further information on how Philips is supporting delirium
prevention, visit VitalMinds.*
[1]] Ouimet S. et al., Intensive Care Med, 2007, 33(1): 66-73[2]
Ely E.W. et al., JAMA, 2004, 291(14): 1753-62[3] S3 guideline for
the management of delirium, analgesia and sedation in intensive
care medicine (DAS guideline 2015),
http://www.awmf.org/leitlinien/detail/ll/001-012.html[4] Luetz A.
et al., Intensive Care Medicine Experimental, 2018, 6 (Suppl
2):40*VitalMinds and VitalSky are not available for sale outside of
the European market.
For further information, please contact:
Kathy O’Reilly Philips Group Press OfficeMobile: +1
978-221-8919E-mail: kathy.oreilly@philips.com
Anke EllingenPhilips GermanyMobile: +49 1522 2814645Email:
Anke.Ellingen@Philips.com
About Royal PhilipsRoyal Philips (NYSE: PHG,
AEX: PHIA) is a leading health technology company focused on
improving people's health and enabling better outcomes across the
health continuum from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. Headquartered in the Netherlands, the company is a
leader in diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as in consumer health
and home care. Philips generated 2018 sales of EUR 18.1 billion and
employs approximately 77,000 employees with sales and services in
more than 100 countries. News about Philips can be found at
www.philips.com/newscenter.
- Philips VitalMinds solution to help prevent delirium
- Philips VitalMinds solution to help prevent delirium 2
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Sep 2023 to Sep 2024